We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cancer Vaccine Collaborative Launched

By Biotechdaily staff writers
Posted on 10 Oct 2002
A research program to improve the way cancer vaccines are developed has been formed by a network of investigators from six New York (NY, USA) medical centers, who are working together as the Cancer Vaccine Collaborative (CVC) to conduct a series of early-stage clinical trials on cancer vaccines. More...
The CVC was launched at the International Cancer Immunotherapy Symposium in New York by two New York research groups: the Cancer Research Institute (www.cancerresearch.org) and the Ludwig Institute for Cancer Research (www.licr.org).

The CVC will test vaccines for several cancer types, including melanoma, sarcoma, and nonsmall cell lung, ovarian, prostate, and bladder cancers. All share the cancer/testis antigen NY-ESO-1, a special marker found almost exclusively in cancer cells. In certain tumors, the marker can become abnormally expressed, acting as a highly specific target for immune cells to attack. Although antigens alone do not elicit a strong enough response to destroy tumors, the researchers hope that vaccinating cancer patients with NY-ESO-1 can help the immune system finish the job.

The participating investigators include researchers from Columbia Presbyterian Medical Center, New York Weill Cornell Medical Center, Mount Sinai School of Medicine, Memorial Sloan-Kettering Cancer Center, and New York University Cancer Institute.

Unlike conventional vaccine trials, where data from one trial are often incomparable to data from another because of uncontrolled variables, CVC trials will use standardized tests to evaluate different ways to deliver the same vaccine agent. This methodology will allow for direct comparison with other CVC trials and show why certain vaccine strategies might result in a more robust immune response while others might not. The studies will be coordinated and conducted in parallel with each other rather than sequentially.

"Testing different vaccine strategies at one time will allow us to more quickly identify the most promising anticancer therapies,” said Dr. Eric Hoffman, director of clinical trials at the Ludwig Institute for Cancer Research. "And because all the research is done using the same methods and techniques, the Cancer Vaccine Collaborative will ensure that data from one trial site can be readily and confidently compared to that of another site.”




Related Links:
Cancer Research Institute
Ludwig Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Pipette Calibration System
Artel PCS®
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.